Stoke Therapeutics Dirección
Dirección controles de criterios 4/4
El CEO de Stoke Therapeutics' es Ed Kaye , nombrado en Oct 2017, tiene una permanencia de 6.5 años. compensación anual total es $3.53M, compuesta por 17.7% salario y 82.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.13% de las acciones de la empresa, por valor de $814.75K. La antigüedad media del equipo directivo y de la junta directiva es de 5.1 años y 5.6 años, respectivamente.
Información clave
Ed Kaye
Chief Executive Officer (CEO)
US$3.5m
Compensación total
| Porcentaje del salario del CEO | 17.7% |
| Permanencia del CEO | 6.6yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 5.2yrs |
| Promedio de permanencia en la Junta Directiva | 5.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
Apr 04Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation
Mar 21
We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Dec 07Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts
May 09Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results
May 06Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business
May 02We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow
Dec 13Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth
Aug 14Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M
Aug 08We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Apr 29Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans
Jan 13We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Sep 30We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Jun 16Stoke Therapeutics EPS misses by $0.02
May 10We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Mar 03Stoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market Cap
Dec 14Stoke Therapeutics prices $97.5M public offering
Nov 20Stoke Therapeutics -2.7% AH, proposes public offering
Nov 18We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Nov 18Stoke Therapeutics EPS in-line
Nov 12Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$109m |
| Dec 31 2023 | US$4m | US$626k | -US$105m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$105m |
| Mar 31 2023 | n/a | n/a | -US$99m |
| Dec 31 2022 | US$6m | US$596k | -US$101m |
| Sep 30 2022 | n/a | n/a | -US$100m |
| Jun 30 2022 | n/a | n/a | -US$96m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$9m | US$568k | -US$86m |
| Sep 30 2021 | n/a | n/a | -US$76m |
| Jun 30 2021 | n/a | n/a | -US$67m |
| Mar 31 2021 | n/a | n/a | -US$58m |
| Dec 31 2020 | US$5m | US$549k | -US$52m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$43m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$668k | US$477k | -US$32m |
| Sep 30 2019 | n/a | n/a | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$21m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | US$1m | US$464k | -US$13m |
Compensación vs. Mercado: La compensación total ($USD3.53M) de Ed está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.42M).
Compensación vs. Ingresos: La compensación de Ed ha sido consistente con los resultados de la empresa en el último año.
CEO
Ed Kaye (74 yo)
6.6yrs
Permanencia
US$3,533,210
Compensación
Dr. Edward M. Kaye, also known as Ed, M.D., Ph.D. has been Special Regulatory and Scientific Advisor of Sarepta Therapeutics, Inc. since June 28, 2017. He serves as Independent Director at Avidity Bioscien...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 6.6yrs | US$3.53m | 0.13% $ 823.2k | |
| Co-Founder & Independent Director | no data | US$198.33k | 0.78% $ 4.8m | |
| Chief Financial Officer | 5.2yrs | US$1.60m | 0.040% $ 246.3k | |
| Chief Medical Officer | 6.6yrs | US$1.65m | 0.0048% $ 29.5k | |
| Co-Founder & Group VP of Discovery Research | no data | sin datos | sin datos | |
| COO & Chief Business Officer | 6.6yrs | US$869.86k | sin datos | |
| Head of Investor Relations | no data | sin datos | sin datos | |
| Corporate Secretary & General Counsel | 3.3yrs | sin datos | 0.0050% $ 30.8k | |
| Chief Communications Officer | 3.3yrs | sin datos | sin datos | |
| Chief Human Resources Officer | 4.6yrs | sin datos | sin datos | |
| Chief Regulatory Officer | 5.4yrs | sin datos | sin datos | |
| Chief Commercial Officer | less than a year | sin datos | sin datos |
5.2yrs
Permanencia media
59yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de STOK es experimentado (5.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 6.6yrs | US$3.53m | 0.13% $ 823.2k | |
| Co-Founder & Independent Director | 9.9yrs | US$198.33k | 0.78% $ 4.8m | |
| Independent Chairman of the Board | 8.8yrs | US$237.33k | 3.6% $ 22.3m | |
| Independent Director | 8.7yrs | US$198.33k | 0.035% $ 213.4k | |
| Independent Director | less than a year | US$394.03k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$199.33k | 0% $ 0 | |
| Independent Director | 3.9yrs | US$206.83k | 0% $ 0 | |
| Independent Director | 4.9yrs | US$209.33k | 0% $ 0 | |
| Independent Director | 5.7yrs | US$211.83k | 0.061% $ 376.7k |
5.7yrs
Permanencia media
60yo
Promedio de edad
Junta con experiencia: La junta directiva de STOK se considera experimentada (5.6 años de antigüedad promedio).